Drug Profile
EP 024297
Alternative Names: EP-024297Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Enanta Pharmaceuticals
- Class
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Non-alcoholic steatohepatitis in USA (PO) (Enanta Pharmaceuticals pipeline, September 2023)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 11 Nov 2016 Updated pharmacodynamics data from preclinical studies in Non-alcoholic steatohepatitis presented at the 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2016)